Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-Grade Serous Ovarian Cancer [0.03%]
空间分辨分子分型揭示高级别浆液性卵巢癌的肿瘤进展和免疫逃逸机制
Yuelei Zhang,Bin Yang,Xin Hou et al.
Yuelei Zhang et al.
High-grade serous ovarian cancer (HGSOC) is a lethal malignancy characterized by profound intratumoral heterogeneity and immune evasion. While previous research has identified four molecular subtypes of HGSOC, defining their spatial distrib...
Justin Powers,Lai Wei,Justin Chak Ting Cheung et al.
Justin Powers et al.
The lethality of pancreatic ductal adenocarcinoma (PDAC) is driven in part by cellular plasticity that facilitates dedifferentiation and dissemination. Although transcriptional programs underlying these processes are well characterized, the...
Fusobacterium nucleatum Promotes Exosomal LncRNA MANCR Secretion from Colorectal Cancer Cells to Induce PD-L1 Expression in Macrophages [0.03%]
核梭杆菌促进结直肠癌细胞外泌体长链非编码RNA MANCR的释放以诱导巨噬细胞PD-L1表达
Shengbo Han,Guozheng Lv,Ping Hu et al.
Shengbo Han et al.
Fusobacterium nucleatum (F. nucleatum) is a key microbial driver of colorectal cancer (CRC) progression. Here, we identified an intercellular signaling axis through which F. nucleatum remodels the immune microenvironment. Analysis of 54 cli...
MPND Loss Epigenetically Activates TGF-β/SMAD3 Signaling to Drive Tumor Progression and Metastasis in Non-small Cell Lung Cancer [0.03%]
MPND通过表观遗传激活TGF-β/SMAD3信号驱动非小细胞肺癌的进展和转移
Jianfeng Yu,Jieru Zhang,Jun Zhang et al.
Jianfeng Yu et al.
Although non-small cell lung cancer (NSCLC) is among the most prevalent malignancies, currently available treatments remain largely ineffective, highlighting the need to elucidate the precise mechanisms of tumorigenesis. The Mpr1/Pad1 N-ter...
Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis [0.03%]
靶向降解体内KRASG12V 使肺腺癌消退并因蛋白酶失调节而复发
Alberto Martín,Inés M García-Pérez,Sonia San José et al.
Alberto Martín et al.
Recent drug discovery breakthroughs led to the approval of KRASG12C inhibitors in lung adenocarcinoma (LUAD). Unfortunately, clinical responses are often hampered by the rapid resistance onset. Proteolysis-targeting chimeras (PROTACs) have ...
Evolutionary antifragile therapy is a treatment strategy to suppress drug resistance by exploiting dose response convexity [0.03%]
利用剂量反应的凸性来抑制药物抗性的一种进化型抗脆弱治疗方法策略
Jeffrey West,Bina Desai,Maximilian A R Strobl et al.
Jeffrey West et al.
A population of cells within a tumor can be described as antifragile (the opposite of fragile) if they derive a benefit from fluctuations or perturbations in environmental conditions induced by treatment. Treatment fluctuations could either...
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma [0.03%]
NRAS突变黑色素瘤中RAS(ON)多选择抑制剂敏感性或耐药性的遗传驱动因素
Mona Foth,Wontak Kim,Kayla OToole et al.
Mona Foth et al.
Most patients with advanced BRAF or NRAS-driven melanoma receive front-line immunotherapy. However, if immunotherapy fails, BRAF-mutated patients have effective second-line therapies, whereas NRAS-mutated patients lack pathway-targeted opti...
Ancestral genetic homogeneity in preclinical models may shape outcome differences in pediatric brain cancer [0.03%]
祖先遗传均一性可能影响儿童脑癌前期模型的预后差异
Alexandra Backlund,Catherine H Samaniego,Rashika Rangaraj et al.
Alexandra Backlund et al.
The influence of genetic ancestry on cancer development and treatment response is underappreciated within pediatric neuro-oncology. Pediatric brain tumors (PBTs) comprise the deadliest malignancies among childhood cancers. Poorer prognoses ...
Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer [0.03%]
应激条件下的信号传导:靶向癌症中的糖皮质激素受体
Melanie S Flint,David M OMalley,Domenica Lorusso et al.
Melanie S Flint et al.
Glucocorticoid receptor (GR) signaling is critical to our physiology but is dysregulated in cancer by the pain, psychological distress, iatrogenic morbidity, and pathology associated with an advanced, invasive disease. Many tumors exploit g...
Armored chimeric antigen receptor T-cell therapy targets antigen-heterogeneous glioma [0.03%]
装甲嵌合抗原受体T细胞疗法靶向抗原异质性胶质瘤
Justin D Clubb,Ryan M Shih,Torahito A Gao et al.
Justin D Clubb et al.
Chimeric-antigen receptor (CAR)-T cell therapy has shown early promise against glioblastoma, which lacks effective treatment options. However, two key challenges curtail efficacy: tumor-antigen heterogeneity and an immunosuppressive tumor m...